News on lab-developed tests and emerging diagnostic technologies.
The team anticipates launching its first clinical diagnostic assay, which will detect targeted, low-frequency genetic mutations in lung cancer, in 2021.
The diagnostic firms were the final companies in the coverage universe of 360Dx to present at the annual conference.
The firm also has an early-access program for a new amplification strategy that combines 11 HLA genes for typing.
Natera discussed its cancer and transplant rejection testing businesses, while Exact Sciences explained how it will benefit from its Genomic Health acquisition.
The financing round comes as Color expands its partnerships with healthcare systems and builds out a national genetic counseling resource for NIH's All of Us program.
